Foreign Industry Unites Against Annual Japan Price Cuts
This article was originally published in PharmAsia News
Executive Summary
Major groups representing the foreign innovation-based pharma and medtech industries in Japan have come out in strong united opposition to a proposal to adopt annual, rather than biennial, reimbursement price cuts, warning this could adversely affect investment and the provision of healthcare.